Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Comparison of the Efficacy of Three Loading Doses of Intravitreal Injection of Conbercept with Injection Combined with PDT for the Treatment of PCV
Beschreibung:
<jats:p><jats:italic>Purpose</jats:italic>. To compare the efficacy between initial 3-monthly intravitreal conbercept monotherapy and combination intravitreal conbercept with photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV). <jats:italic>Methods</jats:italic>. This is a retrospective, comparative study which involved 65 PCV eyes of 65 patients. According to the therapeutic regimen, the PCV patients were divided into two groups: 32 eyes with naive PCV received a PDT after the first intravitreal injection of conbercept (IVC) followed by pro re nata (prn) retreatment (combination group), and 33 eyes with naïve PCV received 3-monthly IVC monotherapy followed by prn regimen (IVC monotherapy group). All patients completed at least 6 months of monthly follow-up. <jats:italic>Results</jats:italic>. At month 6, best-corrected visual acuity (BCVA) improved significantly (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mi>P</mml:mi><mml:mo><</mml:mo><mml:mn>0.05</mml:mn></mml:math>) in both groups compared with that at baseline; the mean changes of BCVA between the IVC monotherapy group and combination group have no significant difference (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mo>−</mml:mo><mml:mn>0.22</mml:mn><mml:mo>±</mml:mo><mml:mn>0.22</mml:mn></mml:math> vs. <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mo>−</mml:mo><mml:mn>0.17</mml:mn><mml:mo>±</mml:mo><mml:mn>0.22</mml:mn></mml:math> LogMAR, <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M4"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.38</mml:mn></mml:math>). The central retinal thickness (CRT) decreased significantly in the two groups (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M5"><mml:mi>P</mml:mi><mml:mo><</mml:mo><mml:mn>0.05</mml:mn></mml:math>), with no difference between the two groups (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M6"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.24</mml:mn></mml:math>). The complete regression rate of polyps was 58.6% (17 out of 29 eyes) in the IVC monotherapy group and 80.65% (25 out of 31 eyes) in the combination group, respectively (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M7"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.09</mml:mn></mml:math>, <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M8"><mml:mi>χ</mml:mi></mml:math>-squared test). The combination group required significantly fewer injections than the IVC monotherapy group (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M9"><mml:mn>3.09</mml:mn><mml:mo>±</mml:mo><mml:mn>0.89</mml:mn></mml:math> vs. <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M10"><mml:mn>3.67</mml:mn><mml:mo>±</mml:mo><mml:mn>0.74</mml:mn></mml:math>, <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M11"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.006</mml:mn></mml:math>). <jats:italic>Conclusion</jats:italic>. Conbercept monotherapy significantly improved visual acuity and effectively regressed polyps during 6-month follow-up time in the treatment of PCV.</jats:p>